The Role of Homocysteine in the Development of Ischemic Stroke in Young Adults (Review of the Literature and Own Observation)

S.K. Yevtushenko, D.A. Filimonov

Abstract


Performed analysis of domestic and foreign literature suggests that hyperhomocysteinemia is an important factor affecting the occurrence and clinical course of ischemic stroke in young people. Own study being conducted, that included 46 patients with established atherothrombotic ischemic stroke, showed that the acute phase of stroke is associated with hyperhomocysteinemia and increased thrombogenic activity of blood. The correlation between the level of homocysteine and adenosine diphosphate-induced platelet aggregation (r = 0.43; p = 0.033), the activity of antithrombin III (r = 0.46; p = 0.036), blood levels of soluble fibrin monomer complex (r = 0.19; p = 0.019), fibrinogen (r = 0.35; p = 0.037), lactate levels (r = 0.37; p = 0.046). We offered to make changes in the existing scheme of ischemic stroke therapy, that will significantly reduce the degree of neurological deficit and promote regression of thrombogenic activity of blood.

Keywords


hyperhomocysteinemia; ischemic stroke; antithrombin III; lactate

References


Дзяк Л.А. Инсульт у пациентов молодого возраста / Л.А. Дзяк, Е.С. Цуркаленко // Практическая ангионеврология. — 2010. — № 2. — С. 9-14.

Евтушенко С.К. Гетерогенный ишемический инсульт у детей / С.К. Евтушенко // Новости медицины и фармации. — 2010. — № 370. — С. 56-61.

Евтушенко С.К. От безмолвных болезней малых сосудов к немым инфарктам / С.К. Евтушенко // Материалы конференции «Рациональная фармакотерапия в неврологии». — К., 2013. — С. 62-68.

Зинкович И.И., Шатова О.П., Трунова О.А. Влияние лактата на миграционную активность лейкоцитов периферической крови // Университетская клиника (Донецк). — 2010. — Т. 6, № 1–2. — С. 49-51.

Зозуля І.С. Гіпергомоцистеїнемія та інші метаболічні предиктори розвитку і перебігу ішемічного інсульту / Зозуля І.С., Шевчук В.І., Безсмертна Г.В. — К.: Національна медична академія післядипломної освіти імені П.Л. Шупика, 2011. — C. 34-36, 124-25.

Мищенко Т.С. Факторы риска и клинические особенности у больных с различными подтипами ишемического инсульта / Т.С. Мищенко, Н.В. Овсянникова, В.В. Лебединец // Международный медицинский журнал. — 2011. — № 3. — С. 27-32.

Суслина З.А. Ишемический инсульт: сосуды, сердце, кровь // Журнал неврологии и психиатрии имени С.С. Корсакова. — 2007. — С. 250-259.

Федин А.И. Гипергомоцистеинемия как фактор риска инсульта / А.И. Федин, В.С. Ефимов, А.З. Кашежева, М.А. Кромм // Журнал неврологии и психиатрии (Приложение «Инсульт»). — 2002. — № 6. — С. 24-28.

Филимонов Д.А. Взаимоотношения гомоцистеина с системой гемостаза и возможности медикаментозной коррекции у пациентов с цереброваскулярной патологией и факторами риска ее развития / Д.А. Филимонов, С.К. Евтушенко, Д.Ш. Дюба, В.А. Симонян // Український вісник психоневрології. — 2012. — Т. 20, № 3 (72). — С. 147.

Perna A.F. Homocysteine and oxidative stress / A.F. Perna, D. Ingrosso, N.G. De Santo // Amino Acids. — December 2003. — Vol. 25, Issue 3–4. — Р. 409-417.

Albert C.M., Cook N.R., Gaziano J.M., Zaharris E., MacFadyen J., Danielson E., Buring J.E., Manson J.E. Effect of folic acid and B vitamins on risk ofcardiovascular events and total mortality among women at high risk forcardiovascular disease: a randomized trial // JAMA. — 2008. — 299. — 2027-2036.

Andrew H. Ford. Plasma homocysteine and MTHFRC677T polymorphism as risk factors for incident dementia / Andrew H. Ford, Leon Flicker, Helman Alfonso, Graeme J. Hankey, Paul E. Norman, Frank M. van Bockxmeer, Osvaldo P. Almeida // J. Neurol. Neurosurg. Psychiatry. — 2012. — 83. — 70-75. doi:10.1136/jnnp.2011.242446

Anthony S. Wierzbicki. Homocysteine and cardiovascular disease: a review of the evidence / Anthony S. Wierzbicki // Diabetes and Vascular Disease Research. — 2007. — 4. — 143. DOI: 10.3132/dvdr.2007.033

A. David Smith, Per M. Ueland et al. // The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with Disease.

Bonaa K.H., Njolstad I., Ueland P.M., Schirmer H., Tverdal A., Steigen T., Wang H., Nordrehaug J.E., Arnesen E., Rasmussen K. Homocysteine Lowering and Cardiovascular Events after Acute Myocardial Infarction (PDF) // N. Engl. J. Med. — 2006. — 354 (15). — 1578. doi:10.1056/NEJMoa055227. PMID 16531614

Champe P., Harvey R. Biochemistry. Lippincott's Illustrated Reviews 4th ed. / P. Champe, R. Harvey. — Philadelphia: Lippincott Williams and Wilkins, 2008. — P. 261-276.

Coen D.A. Stehouwer. Homocysteine-lowering treatment: an overview / Coen D.A. Stehouwer, Coen van Guldener // Expert Opinion on Pharmacotherapy — 2001. — № 2 (9). — P. 1449-1460.

Collins R., Armitage J. Study of the effectiveness of additional reductionsin cholesterol and homocysteine. — 2008: http://directnews.americanheart.org/extras/pdfs/search_slides.pdf Accessed June 1, 2009.

Dietrich-Muszalska A., Malinowska J., Olas B. et al. The oxidative stress may be induced by the elevated homocysteine in schizophrenic patients // Neurochem. Res. — 2012. — 37 (5). — 1057-62. doi:10.1007/s11064-012-0707-3

Donnan G. Stroke / G. ADonnan, M. Fisher, M. Macleod, S. MDavis // The Lancet. — 2008. — № 371. — P. 1612-1623.

Elsayed Z. Soliman. Homocysteine, vitamins, and vascular disease prevention / Elsayed Z. Soliman // American Journal of Clinical Nutrition. — 2007. — № 86. — P. 1563-1568.

Goldstein L.B., Bushnell C.D., Adams R.J., Appel L.J., Braun L.T., Chaturvedi S., Creager M.A., Culebras A., Eckel R.H., Hart R.G., Hinchey J.A., Howard V.J., Jauch E.C., Levine S.R., Meschia J.F., Moore W.S., Nixon J.V., PearsonT.A. Guidelines for the primary prevention of stroke. A guideline for bhealthcare professionals from the American Heart Association/AmericanStroke Association // Stroke. — 2010 Dec. — 6.

Gugliucci A. Antithrombin activity is inhibited by acrolein and homocysteine thiolactone: Protection by cysteine / Gugliucci A. // Life Sci. — 2008. — № 82 (Feb 13). — P. 413-418.

Havva Sahin Kavakli. Homocysteine Levels in Acute Ischemic Stroke Patients / Havva Sahin Kavakli, Neriman Defne Altintas, Tanriverdi Fatih // Journal of Academic Emergency Medicine. — 2010. DOI:http://www.doaj.org/doajifunc = openurl&genre = article&issn = 1305760X&date = 2010&vo-lume = 09&issue = 04&spage = 169

Helga Refsum. The Hordaland Homocysteine Study: A Community-Based Study of Homocysteine, Its Determinants, and Associations with Disease.

Homocysteine Impairs the Nitric Oxide Synthase Pathway / Markus C., Stuhlinger P.S., Tsao Jeng-Horng Her., M. Kimoto et al. // Circulation. — 2001. — № 104. — P. 2569-2575.

Homocysteine Studies Collaboration. Homocysteine and risk of ischemicheart disease and stroke: a meta-analysis // JAMA. — 2002. — 288. — 2015-2022.

Howard V.J., Sides E.G., Newman G.C., Cohen S.N., Howard G., Malinow M.R., Toole J.F. Changes in plasma homocysteine in the acute phase after stroke // Stroke. — 2002. — 33. — 473-78.

Jardine M.J., Kang A., Zoungas S., Navaneethan S.D., Nino-miya T., Nigwekar S.U., Gallagher M.P., Cass A., Strippoli G., Perkovic V. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis // BMJ (Clinical research ed.). — 2012. — 344: e3533. PMC 3374481.

Karolczak K. Mechanism of Action of Homocysteine and Its Thiolactone in Hemostasis System / K. Karolczak, B. Olas // Physiology — 2009. — № 58 — P. 623-633.

Kernagis D.N. Evolving role of biomarkers in acute cerebrovascular disease / Kernagis D.N., Laskowitz D.T. // Ann Neurol. — 2012. — № 71 (3). — P. 289-303.

Kilmer S. McCully. Chemical Pathology of Homocysteine. IV. Excitotoxicity, Oxidative Stress, Endothelial Dysfunction, and Inflammation / Kilmer S. McCully // Ann Clin. Lab. Sci. — 2009. — Vol. 39, № 3. — P. 219-232.

Kilmer S. McCully. The Biomedical Significance of Homocysteine / Kilmer S. McCully // Journal of Scientific Exploration. — 2001. — Vol. 15, № 1. — Р. 5-20.

Lee M., Hong K.S., Chang S.C., Saver J.L. Efficacy of homocysteinelowering therapy with folic acid in stroke prevention: a meta-analysis // Stroke. — 2010. — 41. — 1205-1212.

Liao D., Tan H., Hui R., Wang H. Hyperhomocysteinemia decreasescirculating high-density lipoprotein by inhibiting apolipoprotein A-Iprotein synthesis and enhancing HDL cholesterol clearance // Circ. Res.— 2006. — 99. — 598-606.

Lentz S.R., Haynes W.G. Homocysteine: Is it a clinically important cardiovascular risk factor // Clev. Clin. J. Med. — 2004. — V. 71. — Р. 729-734.

Lonn E. Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease / E. Lonn, S. Yusuf, M.J. Arnold et al. // The New England Journal of Medicine. — 2006. — № 354 (15). — P. 1567-1577.

Loscalo J. The oxidant stress of hyperhomocysteinemia // J. Clin. Invest. — 1996. — Vol. 98. — P. 5-7.

Loscalzo J. Homocysteine Trials — Clear Outcomes for Complex Reasons / J. Loscalzo // New England Journal of Medicine. — 2006. — № 354 (15). — P. 1629-1632.

Luepker R.V. WHO MONICA project: what have we learned and where to go from here? / RV Luepker // Public Health Reviews. — 2011. — № 33. — P. 373-396.

Marti-Carvajal A.J., Solà I., Lathyris D., Salanti G., Marti-Carvajal, Arturo J. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2009 (4): CD006612. doi:10.1002/14651858.CD006612.pub2. PMID 19821378.

Mattson M.P., Culmsee C., Yu Z.F. Apoptotic and antiapoptotic mechanisms in stroke // Cell. Tissue Res. — 2000. — 301. — 173-87.

Meng R. Antithrombin III associated with fibrinogen predicts the risk of cerebral ischemic stroke / Meng R., Li Z.Y., Ji X., Ding Y., Meng S., Wang X. // Clin. Neurol. Neurosurg. — 2011. — № 113 (5). — P. 380-386.

Millen B.E. Nutritional research within the Framingham Heart Study / B.E. Millen, P.A. Quatromoni // The Journal of Nutrition Health and Aging. — 2001. — № 5 (3). — P. 139-143.

Miniňo A.M. Deaths: Final data for 2008 / A.M. Miniňo, S.L. Murphy, J. Xu, K.D. Kochanek // National Vital Statistics Reports. — 2011. — № 8 (7). — P. 9-11.

Nelson D.L. Lehninger Principles of Biochemistry / D.L. Nelson, M.M. Cox. — 3rd ed. — New York: Worth Publishers, 2000. — P. 640-642.

Qujeq D., Omran T.S., Hosini L. Correlation between total homocysteine,low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in the serum of patients with myocardial infarction // Clin. Biochem. — 2001. — 34. — 97-101.

Recep Aygul. Plasma and cerebrospinal fluid homocysteine, nitric oxide and malondialdehyde levels in acute ischemic stroke: possible role of free radicals in the development of brain injury / Recep Aygul, Dilcan Kotan, Abdulkadir Yildirim, Hizir Ulvi, Fatih Akcay // Eur. J. Gen. Med. — 2008. — 5 (2). — 57-63.

Roblin X. Steatosis, chronic hepatitis virus C infection and homocysteine / Roblin X., Pofelski J., Zarski J.P. // Gastroenterol. Clin. Biol. — 2007. — 31 (4). — P. 415-420.

Romero J. Prevention of ischemic stroke: overview of traditional risk factors / J.R. Romero // Current Drug Targets. — 2007. — № 8 (7). — P. 794-801.

Sandercock P. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial / P. Sandercock // The Lancet Neurology. — 2010. — № 10 (10). — P. 855-865.

Saposnik G. Meta analysis suggests that folic acid supplementation doesnot reduce risk of stroke, but there may be some benefit when given incombination with vitamins B6 and B12 and in primary prevention // Evid. Based Med. — 2010. — 15. — 168-170.

Selhub J. Homocysteine metabolism // Annual Review of Nutrition. — 1999. — 19. — 217-246. doi:10.1146/annurev.nutr.19.1.217

Shirodaria C., Antoniades C., Lee J., Moat S.J. Global improvement ofvascular function and redox state with low-dose folic acid: implicationsfor folate therapy in patients with coronary artery disease // Circulation. — 2007. — 115. — 2262-2270.

Smach M.A., Jacob N., Golmard J.L. et al. Folate and homocysteine in the cerebrospinal fluid of patients with Alzheimer’s disease or dementia: a case control study // European Neurology. — 2011. — 65 (5). — 270-8. doi:10.1159/000326301

Spence J.D., Bang H., Chambless L.E., Stampfer M.J. Vitamin interventionfor stroke prevention trial: an efficacy analysis // Stroke. — 2005. — 36. — 2404-2409.

Spence J.D. Homocysteine-lowering therapy: a role in stroke prevention // Lancet Neurol. — 2007. — 6. — 830-838.

Stabler S.P. Vitamin B12 deficiency as a worldwide problem / S.P. Stabler, R.H. Allen // Annual Review of Nutrition. — 2004. — № 24. — P. 299-326.

Sudha Seshadri. Association of Plasma Homocysteine Le-vels with Subclinical Brain Injury: Cerebral Volumes, White Matter Hyperintensity and Silent Brain Infarcts on Volumetric MRI in the Framingham Offspring Study / Sudha Seshadri et al. // Arch. Neurol. — 2008 May. — № 65 (5). — P. 642-649.

Thambyrajah J. Homocysteine and atherothrombosis — mechanisms for injury / J. Thambyrajah, J.N. Townend // European Heart Journal. — 2000. — № 21. — P. 967-974.

Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardiocerebrovascular risk / E. Trabetti // Journal of applied genetics. — 2008. — № 49 (3). — P. 267-282.

Undas A. Homocysteine and thrombosis: from basic science to clinical evidence / Undas A., Brozek J., Szczeklik A. // Thromb. Haemost. — 2005 Nov. — 94 (5). — 907-15.

Vermeer S.E. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study / Vermeer S.E., Van Dijk E.J., Koudstaal P.J., Oudkerk M., Hofman A., Clarke R., Breteler M.M. // Annals of neurology. — 2002. — № 51 (3). — P. 285-289.

Vitvitsky V. Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia / Vitvitsky V., Dayal S., Stabler S., Zhou Y., Wang H., Lentz S.R., Banerjee R. // Am. J. Physiol. Regul. Integr. Comp. Physiol. — 2004. — № 287. — P. 39-46.

Wang H., Fan D., Zhang H., Fu Y., Zhang J., Shen Y. Serum level ofhomocysteine is correlated to carotid artery atherosclerosis in Chinesewith ischemic stroke // Neurol. Res. — 2006. — 28. — 25-30.

Wang X., Qin X., Demirtas H., Li J., Mao G., Huo Y., Sun N., Liu L., Xu X. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis // Lancet. — 2007. — 369. — 1876-1882.

Williams K.T. Homocysteine metabolism and its relation to health and disease / K.T. Williams, K.L. Schalinske // Biofactors. — 2010. — № 36. — Р. 19-24.

Yang Q., Botto L.D., Erickson J.D., Friedman J.M. Improvement in strokemortality in Canada and the United States, 1990 to 2002 // Circulation. — 2006. — 113. — 1335-1343.

Zhang F., Slungaarg A., Vercellotti G.M., Iadecola C. Superoxide-dependent cerebrovascular effects of homocysteine // Am. J. Physiol. — 1998. — 274. — 1704-11.




DOI: https://doi.org/10.22141/2224-0713.7.61.2013.86060

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru